KLHDC7B

Across TCGA pan-cancer cohorts, KLHDC7B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KLHDC7B data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher KLHDC7B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KLHDC7B expression acts as an unfavorable survival marker.

CESC, BLCA, and LUSC are the cancer types where KLHDC7B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.109	0.597	<.001	36	view →
BLCA	OS	Median	IV	0.128	0.593	<.001	33	view →
LUSC	DFS	Median	All	0.010	0.792	<.001	24	view →
KIRC	OS	Median	All	0.182	0.805	.003	15	view →
LUAD	OS	Median	All	0.254	0.697	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KLHDC7B–CESC (OS)

Open the CESC breakdown →